Revdofilimab
- Generic Name
- Revdofilimab
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT04196283
- Locations
- πΊπΈ
The University of Chicago Medical Center /ID# 217196, Chicago, Illinois, United States
πΊπΈMD Anderson Cancer Center /ID# 214041, Houston, Texas, United States
πΊπΈNorton Cancer Institute /ID# 216179, Louisville, Kentucky, United States
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Advanced Solid TumorsCancerTriple-Negative Breast Cancer (TNBC)Non-small-cell-lung-cancer (NSCLC)Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT03893955
- Locations
- πͺπΈ
Hospital Universitario Fundacion Jimenez Diaz /ID# 212806, Madrid, Spain
π¦πΊIcon Cancer Centre /ID# 224084, South Brisbane, Queensland, Australia
πΊπΈFort Wayne Medical Oncology and Hematology, Inc /ID# 226072, Fort Wayne, Indiana, United States
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3
- Registration Number
- NCT03818542
- Locations
- πΊπΈ
Massachusetts General Hospital /ID# 207392, Boston, Massachusetts, United States
πΊπΈUniversity of Michigan /ID# 210181, Ann Arbor, Michigan, United States
πΊπΈMD Anderson Cancer Center /ID# 208749, Houston, Texas, United States
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 139
- Registration Number
- NCT03071757
- Locations
- π«π·
Institut Gustave Roussy /ID# 165035, Villejuif Cedex, Val-de-Marne, France
π«π·AP-HM - Hopital de la Timone /ID# 165036, Marseille CEDEX 05, Bouches-du-Rhone, France
πΊπΈCarolina BioOncology Institute /ID# 160786, Huntersville, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.